Lonza Group Ltd today announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement.

This agreement will supplement existing production of Alexion products at multiple Lonza facilities.

The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza’s proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

“I’m pleased to be reinforcing our long-standing strategic relationship with Alexion,” said Marc Funk, COO of Lonza. “Our new offering of suites with dedicated manufacturing capacity will give customers greater flexibility in determining production quantities and timings. At the same time, we’ll continue to offer our services in our multi-purpose plants to meet our customers’ needs.”

“Alexion is pleased to further enhance our manufacturing network with Lonza,” said Julie O’Neill, Executive Vice President, Global Operations at Alexion. “Developing a robust supply chain for our pipeline and commercial products is essential as we aim to serve more patients with our growing portfolio of life-transforming therapies.”